Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
NeuroMetrix
(NASDAQ:NURO)
Intraday
$4.30
0.65
[17.81%]
After-Hours
$4.30
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$4.30
0.65
[17.81%]
At close: Apr 19
$4.30
0
[0.00%]
After Hours: 6:10PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for NeuroMetrix Stock (NASDAQ:NURO)
NeuroMetrix Stock (NASDAQ: NURO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 19, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
22 hours ago
NeuroMetrix Appoints Joshua S. Horowitz As New Independent Director; Co. Also Terminates At-The-Market Equity Facility
Benzinga Newsdesk
-
1 day ago
Thursday, March 14, 2024
NeuroMetrix Publishes Study Demonstrating That DPNCheck Diagnoses Diabetic Peripheral Neuropathy
Benzinga Newsdesk
-
Mar 14, 2024, 9:01AM
Wednesday, March 13, 2024
NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Benzinga Newsdesk
-
Mar 13, 2024, 9:08AM
Monday, March 04, 2024
Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"
Benzinga Newsdesk
-
Mar 4, 2024, 8:08AM
Thursday, February 22, 2024
NeuroMetrix Q4 EPS $(1.43) Down From $(0.73) YoY, Sales $1.32M Down From $1.85M YoY
Benzinga Newsdesk
-
Feb 22, 2024, 7:02AM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Tuesday, February 20, 2024
NeuroMetrix 13G Filing Shows RS Fund LP Reported A 14.4% Stake In The Co As Of February 13, 2024
Benzinga Newsdesk
-
Feb 20, 2024, 2:58PM
Tuesday, February 13, 2024
NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value
Benzinga Newsdesk
-
Feb 13, 2024, 9:03AM
Tuesday, December 12, 2023
NeuroMetrix Reported The Recent Presentation Of Data From A Clinical Trial Of Quell Wearable Neuromodulation Technology In Patients With Post-Acute Covid-19 Syndrome
Benzinga Newsdesk
-
Dec 12, 2023, 9:03AM
Tuesday, December 05, 2023
NeuroMetrix Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy
Benzinga Newsdesk
-
Dec 5, 2023, 9:01AM
Wednesday, November 22, 2023
NeuroMetrix Shares Resume Trade
Benzinga Newsdesk
-
Nov 22, 2023, 9:00AM
NeuroMetrix Shares To Resume Trade At 9:00 A.M.. ET
Charles Gross
-
Nov 22, 2023, 7:40AM
Monday, November 20, 2023
NeuroMetrix Announces 1-For-8 Reverse Stock Split
Benzinga Newsdesk
-
Nov 20, 2023, 9:01AM
Friday, November 10, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Nov 10, 2023, 4:31PM
Thursday, October 26, 2023
NeuroMetrix shares are trading lower after the company reported Q3 financial results.
Benzinga Newsdesk
-
Oct 26, 2023, 11:59AM
Earnings Scheduled For October 26, 2023
Benzinga Insights
-
Oct 26, 2023, 7:20AM
NeuroMetrix Q3 GAAP EPS $(0.21) Up From $(0.23) YoY, Sales $1.20M Down From $1.97M YoY
Benzinga Newsdesk
-
Oct 26, 2023, 7:06AM
Monday, October 02, 2023
NeuroMetrix And The National Fibromyalgia Association To Collaborate To Improve The Quality Of Life For People Living With Fibromyalgia
Benzinga Newsdesk
-
Oct 2, 2023, 9:01AM
Tuesday, September 26, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 26, 2023, 12:04PM
Monday, August 28, 2023
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Aug 28, 2023, 1:52PM
Wednesday, August 23, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Aug 23, 2023, 1:16PM
Tuesday, August 22, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 22, 2023, 1:51PM
Monday, August 14, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 14, 2023, 1:48PM
Tuesday, August 01, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 1, 2023, 3:06PM
Thursday, July 27, 2023
NeuroMetrix Q2 EPS $(0.19) Down From $(0.17) YoY, Sales $1.65M Down From $2.14M YoY
Benzinga Newsdesk
-
Jul 27, 2023, 7:13AM
Earnings Scheduled For July 27, 2023
Benzinga Insights
-
Jul 27, 2023, 4:34AM
Thursday, June 01, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jun 1, 2023, 12:59PM
Wednesday, May 31, 2023
NeuroMetrix Shares Quell Clinical Trial Results For Chemotherapy Induced Peripheral Neuropathy
Benzinga Newsdesk
-
May 31, 2023, 9:03AM
Monday, May 22, 2023
NeuroMetrix Granted European Patent Number EP3538202 Titled "'ranscutaneous Electrical Nerve Stimulation Using Novel Unbalanced Biphasic Waveform And Novel Electrode Arrangement'
Benzinga Newsdesk
-
May 22, 2023, 2:16PM
Wednesday, May 03, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
May 3, 2023, 1:31PM
NeuroMetrix shares are trading lower after the company reported Q1 EPS and sales results were lower year over year.
Benzinga Newsdesk
-
May 3, 2023, 10:22AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
May 3, 2023, 9:06AM
NeuroMetrix Q1 EPS $(0.20) Down From $(0.14) YoY, Sales $1.70M Down From $2.30M YoY
Benzinga Newsdesk
-
May 3, 2023, 7:04AM
Tuesday, March 21, 2023
NeuroMetrix To Exhibit Quell Fibromyalgia And Present New Clinical Data At The American Academy Of Pain Medicine 2023 Annual Meeting
Happy Mohamed
-
Mar 21, 2023, 9:11AM
Thursday, February 23, 2023
NeuroMetrix Q4 EPS $(0.09) Up From $(0.15) YoY, Sales $1.85M Up From $1.82M YoY
Benzinga Newsdesk
-
Feb 23, 2023, 7:01AM
Earnings Scheduled For February 23, 2023
Benzinga Insights
-
Feb 23, 2023, 5:18AM
Wednesday, January 25, 2023
NeuroMetrix Received Decision To Grant European Patent Titled 'TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION USING NOVEL UNBALANCED BIPHASIC WAVEFORM AND NOVEL ELECTRODE ARRANGEMENT'
Michael Horton
-
Jan 25, 2023, 1:15PM
Monday, January 23, 2023
NeuroMetrix Announces Launch Of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test For Peripheral Neuropathy
Benzinga Newsdesk
-
Jan 23, 2023, 9:16AM
Wednesday, January 11, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Jan 11, 2023, 8:05AM
Tuesday, November 08, 2022
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Nov 8, 2022, 7:11AM
Why TripAdvisor Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket
Lisa Levin
-
Nov 8, 2022, 6:08AM
Thursday, November 03, 2022
NeuroMetrix Announces Strategic Launch Of Quell Fibromyalgia
Benzinga Newsdesk
-
Nov 3, 2022, 9:04AM
Tuesday, November 01, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Nov 1, 2022, 11:48AM
Friday, October 28, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Oct 28, 2022, 12:12PM
Monday, October 24, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 24, 2022, 11:41AM
Friday, October 21, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Oct 21, 2022, 1:26PM
Thursday, October 20, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Oct 20, 2022, 11:46AM
NeuroMetrix shares are trading lower after the company reported Q3 EPS and sales results were down year over year.
Benzinga Newsdesk
-
Oct 20, 2022, 9:04AM
NeuroMetrix Q3 EPS $(0.23) Down From $(0.12) YoY, Sales $2.00M Down From $2.06M YoY
Bill Haddad
-
Oct 20, 2022, 7:06AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch